Agerelated macular degeneration (AMD) is a deterioration or breakdown of the eye’s macula. The macula is a small area in the retina — the light-sensitive tissue lining the back of the eye. The macula is the part of the retina that is responsible for your central vision, allowing you to see fine details clearly.
Wet macular degeneration is a chronic eye disease that causes vision loss in the center of your field of vision. Wet macular degeneration is generally caused by abnormal blood vessels that leak fluid or blood into the region of the macula
 by Patricia Nale
WAILEA, Hawaii – The most significant lesson learned from the HARBOR study is that individualization of patient care achieves best results when it comes to the treatment of age-related macular degeneration, a presenter said here.  “Simply treating all patients the same is not good medicine,” Pravin U. Dugel, MD,said at Retina 2015.
In the HARBOR study, patients with age-related macular degeneration experienced clinically meaningful and similar improvement in visual and anatomic outcomes over 2 years, regardless of dosing regimen with ranibizumab (Lucentis, Genentech). Both monthly and PRN treatment provided rapid and sustained anatomic response, Dugel said. Furthermore, in patients with pigment epithelium detachment (PED) at baseline, vision improved regardless of PED size, treatment regimen or dose, Dugel said.
“I consider this the most relevant level 1 study that we have,” Dugel said, basing his statement on the premise that HARBOR was the first study to use SD-OCT to follow disease and he believes the first study to incorporate PEDs in its retreatment criteria…….
Read More:
Source: Healio